姓名:曲显俊 性别:男 职称:教授 招生院所:基础医学院 招生类型:科学学位(博) 科学学位(硕) 招生专业:药理学(博) 药理学(硕) 研究方向名称:肿瘤药理学 电子信箱:quxj@ccmu.edu.cn
社会任职
1. 中国抗癌协会抗癌药物专业委员会委员
2. 中国药理学会生化与分子药理专业委员会委员
3. 北京市药理学会理事
个人简历
1. 197810-198306:青岛医学院 临床医学专业学习
2. 198307-200111:山东省医学科学院药物研究所 助理研究员、副研究员、研究员
3. 200112-200310:澳大利亚新南威尔斯大学肿瘤研究中心 合作研究
4. 200403-201305:山东大学药学院 教授、博士生导师
5. 200508-200607:东京大学医学部 客员研究员
6. 201305-:首都医科大学基础医学院 教授、博士生导师
重要学术论文
1. Yu-Hang Zhang, Dong-Dong Luo, Sheng-Biao Wan*,Xian-Jun Qu*.S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD. Pharmacological Research. 2020,155:104717.SCI
2. Song ZY,Wang F, Cui SX, Gao ZH*, Qu XJ*.CXCR7/CXCR4 heterodimer-induced histone demethylation: a new mechanism of colorectal tumorigenesis. Oncogene. 2019,38(9):1560-1575.SCI
3. Yu X, Wang D, Wang X, Sun S, Zhang Y, Wang S, Miao R, Xu X, Qu X*.CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. J Exp Clin Cancer Res. 2019,38(1):32.SCI
4. Wang SQ, Yang XY, Xinfeng Yu, Cui SX*, Qu XJ*.Knockdown IGF-1R triggers viral RNA sensors MDA-5- and RIG-I-mediated mitochondrial apoptosis in colonic cancer cells. Molecular Therapy—Nucleic Acids. 2019,16:105-117.SCI
5. Wang SQ, Yang XY, Cui SX*, Gao ZH, Qu XJ*. Heterozygous knockout insulin-like growth factor-1 receptor (IGF-1R) regulates mitochondrial functions and prevents colitis and colorectal cancer. Free Radic Biol Med. 2019,134:87-98.SCI
6. Yu X; Shi W; Zhang Y; Wang X; Sun S; Song Z; Liu M; Zeng Q; Cui S; Qu X*.CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance throughenhancing autophagy in colorectal cancer. Sci Rep. 2017,7:42226.SCI
7. Xinfeng Yu, Aiping Luo, Yicong Liu, Shuqing Wang, Ye Li, Wenna Shi, Zhihua Liu, Xianjun Qu*.MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Molecular Cancer. 2015,14:208.SCI
8. Li YY, Qin YZ, Wang RQ, Li WB, Qu XJ*.SL-01, an oral derivative of gemcitabine, inhibited human breast cancer growth through induction of apoptosis. Biochem Biophys Res Commun. 2013,438:402-409.SCI
9. Zhao CR, Wang RQ, Li G, Xue XX, Sun CJ, Qu XJ*, Li WB. Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines.. Bioorg Med Chem Lett. 2013,23(7):1898-1998.SCI
10. Yue B, Zhao CR, Xu HM, Li YY, Cheng YN, Ke HN, Yuan Y, Wang RQ, Shi YQ, Lou HX, Qu XJ*.Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies. Biochimica et Biophysica Acta (BBA) - General Subjects. 2013,1830(5):2194-2203.SCI
11. Zhao C, Li Y, Qin Y, Wang R, Li G, Sun C, Qu X, Li W.Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. Cancer Chemother Pharmacol. 2013,71(6):1541-1550.SCI
12. Liu HP, Gao ZH, Cui SX, Wang Y, Li BY, Lou HX, Qu XJ*.Chemoprevention of intestinal adenomatous polyposis by acetyl-11-keto-beta-boswellicacid (AKBA) in APC(Min/+) mice.. Int J Cancer. 2013,132(11):2667-81.SCI
13. Yue B, Zhang YS, Xu HM, Zhao CR, Li YY, Qin YZ, Wang RQ, Sun D, Yuan Y, Lou HX, Qu XJ*.Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way. Cancer Lett. 2013,328 :104-113.SCI
14. Xue X, Sun DF, Sun CC, Liu HP, Yue B, Zhao CR, Lou HX, Qu XJ*.Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies. Lung Cancer. 2012,76 :300-308.SCI
15. Yuan C, Zhang YS, Cheng YN, Xue X, Xu WF, Qu XJ*.A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene. Leuk Lymphoma. 2012,53(2):295-304.SCI
16. Zhao CR, Wang RQ, Li G, Xue XX, Sun CJ, Qu XJ*, Li WB.Synthesis and Biological Evaluation of Oral Prodrugs Based on the Structure of Gemcitabine. Chem Biol Drug Des. 2012,80(3):479-88.SCI
17. Zhao C, Yue B, Liu H, Sun C, Li W, Qu X*.SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicol Appl Pharmacol. 2012,262(3):293-300.SCI
18. Hui-Ping Liu, Zu-Hua Gao, Shu-Xiang Cui, De-Fu Sun, Yan Wang, Cui-Rong Zhao, Hong-Xiang Lou, Xian-Jun Qu*.Inhibition of intestinal adenoma formation in APCMin/+ mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsute. Plos. One. 2012,7(3):e33243.SCI
19. Sun DF, Gao ZH, Liu HP, Yuan Y, Qu XJ*.Sphingosine 1-phosphate antagonizes the effect of all-trans retinoic acid (ATRA) in a human colon cancer cell line by modulation of RAR expression. Cancer Lett. 2012,319:182-189.SCI
20. Sun DF;Gao ZH;Liu HP;Yuan Y;Qu XJ*.Sphingosine 1-phosphate antagonizes the effect of all-trans retinoic acid (ATRA) in a human colon cancer cell line by modulation of RAR expression. Cancer Lett. 2012,319:182-189.SCI
21. Xue X, Qu XJ*, Gao ZH, Sun CC, Liu HP, Zhao CR, Cheng YN, Lou HX*.Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Invest New Drugs. 2012,30:212–222.SCI
22. Gao JJ, Gao ZH, Zhao CR, Yuan Y, Cui SX, Zhang XF, Cheng YN, Xu WF, Tang W, Qu XJ*.LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin. Invest New Drugs. 2011,29:574-582.SCI
23. Sun CC, Zhang YS, Xue X, Cheng YN, Liu HP, Zhao CR, Lou HX, Qu XJ*.Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma. Eur J Pharmacol. 2011,667(1-3):136-143.SCI
24. Gao JJ, Xue X, Gao ZH, Cui SX, Cheng YN, Xu WF, Tang W, Qu XJ*.LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo. Microvasc Res. 2011, 82(2):122-30.SCI
25. Pan Yue, Zu-Hua Gao, Xia Xue, Shu-Xiang Cui, Cui-Rong Zhao, Yi Yuan, Zhe Yin, Yoshinori Inagaki, Norihiro Kokudo, Wei Tang, Xian-Jun Qu*.Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signaling pathway. Eur J Cancer. 2011,47 :1115-1124.SCI
26. 【未填作者】.Haishengsu, a protein from shellfish Tegillarca L. granosa, inhibits the growth and the activity of matrix metalloproteinases-2 and -9 in human lung carcinoma. Food Biophys. 2011,6 :390-396.SCI
27. 【未填作者】.Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells. Cancer Lett. 2010,292:153-162.SCI
28. 【未填作者】.N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. Cancer Chemother Pharmacol. 2010,66(1):11-9.SCI
29. 【未填作者】.Nrf2-ARE signaling pathway and natural products for cancer chemoprevention. Cancer Epidemio. 2010,34::523-533.SCI
30. 【未填作者】.Modulation of P-glycoprotein activity by substituted quinoxalinones compound QA3 in adriamycin-resistant K562/A02 cells. Pharmacological Reports. 2010,62:333-342..SCI
31. 【未填作者】.Protective effects of Salvia plebeia compound homoplantaginin on hepatocyte injury. Food Chem Toxicol.. 2009,47:1710-1715. .SCI
32. 【未填作者】.Overcoming multidrug resistance in cancer: an update on research of natural products. Drugs of the Future . 2009,34(1):53-59.SCI
33. 【未填作者】.Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis. 2009,26(5):469-77.SCI
34. 【未填作者】.Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells. Biomedicine & Pharmacotherapy. 2009,63:202-208.SCI
35. 【未填作者】.Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Chemotherapy. 2009,55:28-35.SCI
36. 【未填作者】.Inhibition activity of sulfated polysaccharide of Sepiella maindroni ink on matrix metalloproteinase (MMP)-2 . Biomedicine & Pharmacotherapy. 2008,62(5):297-302.SCI
37. 【未填作者】.Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity. Anticancer Drugs. 2008,19(10):957-965.SCI
38. 【未填作者】.Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sciences. 2008,83:815-820.SCI
主编或副主编的著作/译著
重要奖项
删除或更新信息,请邮件至freekaoyan#163.com(#换成@)
首都医科大学硕士研究生导师教师师资介绍简介-曲显俊
本站小编 Free考研考试/2020-04-27
相关话题/首都医科大学 师资
首都医科大学硕士研究生导师教师师资介绍简介-李晓蓉
姓名:李晓蓉性别:女职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:药物代谢电子信箱:madingdaier@aliyun.com社会任职个人简历重要学术论文主编或副主编的著作/译著重要奖项 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-许焕丽
姓名:许焕丽性别:女职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:抗肿瘤药物药理学电子信箱:**@163.com社会任职个人简历1.200109-200507:山东大学药学院本科生2.200509-201007:山东大学药学院研究生3.200612-201001:日本东京大学医学部联合培养研究生4.201009-201210:中国医学科学院北京协和医学 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-罗大力
姓名:罗大力性别:女职称:教授招生院所:基础医学院招生类型:科学学位(博)科学学位(硕)招生专业:药理学(博)药理学(硕)研究方向名称:心血管系统药理学和细胞内钙信号转导电子信箱:luodl@ccmu.edu.cn社会任职个人简历1.199110-199210:日本新泻大学医学部药理系学习2.199709-200110:哈尔滨医科大学药理室教授及系副主任3.199809-200106:哈尔滨医科大 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-周雪林
姓名:周雪林性别:男职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:天然药物药理学与药代动力学电子信箱:zhouxuelin@ccmu.edu.cn社会任职1.中国药理学会分析药理专业委员会青年委员会委员2.北京药理学会药物代谢专业委员会委员个人简历1.200109-200507:中国药科大学生命科学与技术学院本科生2.200509-200807:中国药 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-郑元元
姓名:郑元元性别:女职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:心血管药理学电子信箱:zhengyy@ccmu.edu.cn社会任职个人简历1.199909-200307:北京大学医学部本科2.200309-200607:中国协和医科大学硕士研究生3.200609-201012:美国肯塔基大学博士研究生4.201101-201202:雀巢(中国)有限 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-范征
姓名:范征性别:女职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:帕金森病的发病机制及药物防治研究电子信箱:fanzheng@ccmu.edu.cn社会任职1.中国药理学会神经精神药理学专业青年委员会委员2.北京药理学会神经精神药理学专业青年委员会委员个人简历1.200809-201106:吉林大学攻读博士学位2.201112-201310:南京医科大学 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-熊杰
姓名:熊杰性别:女职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:药理学电子信箱:xiongjie@ccmu.edu.cn社会任职个人简历重要学术论文主编或副主编的著作/译著重要奖项 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-金增亮
姓名:金增亮性别:男职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:神经精神药理及新药研发电子信箱:**@163.com社会任职1.北京药理学会神经精神药理学专业委员会青年委员2.中国药理学会神经精神药理专业委员会青年委员个人简历1.200709-201207:南方医科大学学习2.200802-201007:军事医学科学院毒物药物研究所学习3.20100 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-薛明
姓名:薛明性别:男职称:研究员、教授招生院所:基础医学院招生类型:科学学位(博)科学学位(硕)招生专业:药理学(博)药理学(硕)研究方向名称:物质代谢与低氧组学电子信箱:xuem@ccmu.edu.cn社会任职1.中国药理学会常务理事2.北京药理学会副理事长3.中国微纳米技术学会理事4.中国药理学会药物代谢\网络药理\药源性疾病专委会委员5.中国药理学会分析药理\肾脏药理专委会常务委员6.北京生理 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27首都医科大学硕士研究生导师教师师资介绍简介-肇玉明
姓名:肇玉明性别:女职称:副教授招生院所:基础医学院招生类型:科学学位(硕)招生专业:药理学(硕)研究方向名称:神经退行性疾病的机制及新药研发电子信箱:yumingzhao@ccmu.edu.cn社会任职1.中国卒中学会新药研发与评价分会理事2.中国生物物理学会自由基生物学与自由基医学专业委员会青年理事3.中国药理学会会员个人简历1.199408-199907:大连医科大学临床药学系本科学习2.1 ...首都医科大学考研导师 本站小编 Free考研考试 2020-04-27